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Background: Glioblastoma stem-like cells (GSC) have been shown to promote tumor growth, tumor-associated
neovascularization, therapeutic resistance, and metastasis. CXCR4 receptors have been found involved in the
proliferation, metastasis, angiogenesis, and drug-resistant characteristics of glioblastoma. However, the role of
CXCR4 in modulating the stem-like cell properties of rat glioblastoma remains ambiguous.
Methods: To explore the role of the CXCL12/CXCR4 axis in maintaining rat GSC properties, we disrupted the CXCR4
signaling by using small hairpin interfering RNA (shRNA). To investigate the role of the CXCL12/CXCR4 axis in
maintaining rat GSC properties, we used a spheroid formation assay to assess the stem cell self-renewal properties.
A western blot analysis and PCR arrays were used to examine the genes involved in proliferation, self-renewal, and
cancer drug resistance. Finally, DNA content and flow cytometry, an immunohistochemical analysis, and
methylcellulose colony formation, in vitro invasive and intracranial injection xenograft assays were employed to
examine the disruptive effect of CXCR4 on the characteristics of GSCs of the RG2 cell line.
Results: Disrupting CXCR4 inhibited the proliferation of RG2 cells both in vitro and in vivo. The spheroid formation
assay indicated that CXCR4 was vital for the self-renewal of RG2 GSCs. Disrupting the CXCL12/CXCR4 pathway also
reduced the expression of GSC cell markers, including Nestin, ABCG2, and musashi (Msi), and the expression of
genes involved in regulating stem cell properties, including Oct4, Nanog, maternal embryonic leucine zipper kinase
(MELK), MGMT, VEGF, MMP2, and MMP9.
Conclusion: The chemokine receptor CXCR4 is crucial for maintaining the self-renewal, proliferation, therapeutic
resistance, and angiogenesis of GSCs of rat RG2 glioblastoma.
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Despite continual advances in surgical techniques, chemo-
therapy, and radiation regimens, the survival rate of pa-
tients with glioblastoma multiforme (GBM) remains bleak
[1,2]. Recent studies have suggested that the progression
of these brain tumors is driven by a small subpopulation
of tumor cells known as cancer stem cells (CSCs), which
can self-renew, proliferate, and generate a progeny of mul-
tiple neuroepithelial lineages [3]. Glioblastoma stem-like
cells (GSCs) are critical promoters of tumor growth,* Correspondence: 059271@mail.fju.edu.tw
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reproduction in any medium, provided the ortumor-associated neovascularization, therapeutic resist-
ance, and metastasis, [4-6] and are vital to an aggressively
invasive phenotype of GBM [7]. These studies have sug-
gested that targeting GSCs can reduce tumor recurrence
and substantially enhance GBM treatment.
CXCR4, a member of the large family of 7-transmembrane
domain receptors, is coupled with heterotrimeric Gi pro-
teins and activated by its ligand CXCL12 (SDF-1). Recent
studies have indicated that the CXCL12/CXCR4 axis regu-
lates tissue-specific stem cell proliferation, survival, and
homing [8,9]. In addition, CXCR4 is the most common
chemokine receptor expressed in cancer cells, including
breast, pancreatic, and prostate cancers, and GBM [10,11].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Disruption of CXCR4 abrogated signal transduction
pathways and the proliferation of rat glioblastoma, RG2.
(A) Representatives of combined individual clones with similar
residual levels of CXCR4 from the rat glioblastoma cell line (RG2)
with disrupted expression of CXCR4 by shRNA. Both western
blotting and RT-PCR revealed decreased levels of CXCR4 in
shrCXCR4-1 and shrCXCR4-3 clones, compared to the mock shGFP.
(B) Disruption of CXCR4 impaired the phosphorylation of AKT and ERK
without (AKT-p, ERK-p) or with induction of SDF1α (AKT-p/SDF-1, ERK-p/
SDF-1α). (C) In vitro transwell assay indicated that inhibiting CXCR4 did
not affect the invasiveness of RG2. (D) Methylcellulose colony formation
assays indicated that the disruption of CXCR4 reduced the number of
colonies. As shown was representative of similar results from two
independent experiments.
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several CSCs, including GSC [8,12]. Studies have also
demonstrated that the activation of CXCR4 by CXCL12
stimulates a specific and significant proliferative response
in GSCs, but not in differentiated tumor cells [13]. How-
ever, the exact role of and mechanisms by which the
CXCL 12/CXCR4 axis in GSCs promotes tumor prolifera-
tion and tumor-associated neovascularization remain am-
biguous, and corresponding therapeutic treatments have
yet to be identified.
Rat RG2 glioblastoma, which has a highly invasive
growth pattern, is an effective GBM model that has been
used in various preclinical studies to evaluate changes in
vascular permeability [14]. After using the RG2 model, our
findings indicated that the CXCL12/CXCR4 axis conveyed
signals by using the AKT, and Erk pathways, demonstrat-
ing that CXCR4 contributes to the proliferation, but not
the invasiveness, of in vitro RG2. Disrupting the CXCR4
impaired the drug resistance if RG2 and the self-renewal
properties of in vitro GSCs, but it did not affect in vivo
tumorigenesis. Furthermore, we observed changes in the
levels of several molecules involved in the self-renewal,
proliferation, drug resistance, and vascularization of GSCs
that resulted from a decrease in the level of CXCR4. Our
data suggest that CXCR4 modulates the progress of glio-
blastoma by maintaining the properties of GSCs.
Results and discussion
Disrupting CXCR4 abrogated the SDF-1/CXCR4 axis signal
transduction pathways
We investigated the correlation between CXCR4 levels and
clinical pathological statuses; the results indicated that a
high level of CXCR4 was associated with malignant tumors
(Additional file 1: Figure S1, Additional file 2: Table S1),
which was consistent with the reports of previous studies.
These findings suggest that CXCR4 plays a role in the pro-
gress of primary tumors. To investigate the role of CXCR4
in tumor progression, we screened the level of CXCR4 of
several glioblastoma cell lines derived from humans, mice,
and rats. Of these glioma cell lines, RG2, a rat glioblastoma
cell line, was selected because it exhibits a high level of
CXCR4 expression, highly invasive growth, and similar in-
vasion patterns to human gliomas [15,16].
Short-hairpin (shRNA)-containing plasmids that target
the nucleotides of CXCR4 and control sequences of GFP
were separately introduced into RG2 cell lines. The re-
sidual CXCR4 expression of selected clones was deter-
mined using western blotting and PCR. Two to three
separate clones that possessed similar residual levels of
CXCR4 were pooled together. Clones that possessed
varying residual CXCR4 expressions and controls were
designated shrCXCR4-3 (< 50%), shrCXCR4-1 (< 20%),
and shGFP, and were chosen for further characterization
(Figure 1A). The SDF-1 levels of the selected clonesremained unchanged (Figure 1A, SDF-1). To investigate
how disrupting CXCR4 expression affects the signal trans-
duction pathway [17,18], cells were harvested after being
treatment using or not using SDF-1, and the levels of
phosphorylated ERK and AKT were determined. The re-
sults indicated that interrupting CXCR4 reduces both
AKT and ERK phosphorylation in a dose-dependent fash-
ion (Figure 1B). The methylcellulose colony formation and
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CXCR4 axis is required for cell growth but not for the
in vitro invasiveness of RG2 (Figure 1C, D). Subcutaneous
injections of shGFP and shrCXCR4-1 into NOD-SCID
mice revealed that disrupting CXCR4 impaired the prolif-
eration of glioblastoma but not in vivo tumorigenesis
(Additional file 3: Figure S2).Disrupting CXCR4 expression impaired sphere formation
in glioblastoma stem-like cells (GSCs) of RG2
Several studies have indicated that CD133+ or CD133-
glioma cells have a stem-like cell population and can
cause tumors [19,20]. We investigated the CD133 level
of rat RG2 glioblastoma; the flow cytometry and RT-
PCR results showed that the expression of CD133 in
RG2 was low (Figure 2A). To investigate the role of
CXCR4 in regulating the characteristics of CSCs, we
tested sphere formation by using an ultralow plate sys-
tem and a modified plate-well designed to test self-
renewal properties by preventing cell attachment and
differentiation. The result showed that the shrCXCR4-1
RG2 significantly lost its ability to form spheres
(Figures 2B-D). We performed cell cycle analysis to de-
termine whether the reduction number and sphere size
were caused by the increase of apoptotic cells or the re-
duction in proliferation. As shown in Figure 2E, the
percentage of G2/M populations within cells collected
from shrCXCR4-1 spheres was higher (S-shrCXCR4,
19.5 ± 0.7%) than those from shGFP spheres (S-shGFP,
15.5 ± 0.6%), but the apoptotic population remained
comparable (S-shGFP: 0.17 ± 0.02% vs. S-shrCXCR4-1:
0.17 ± 0.05%). By contrast, the percentage of G1 popula-
tions within the cells collected from shrCXCR4-1 (68 ±
0.8%) was lower than those from shGFP (72 ± 1.5%)
(Figure 2E). This observation indicates that the reduc-
tion number and sphere size may be due to the reduc-
tion in proliferation. However, the in vivo data showed
that disruption of CXCR4 impaired proliferation and in-
creased apoptosis of RG2 glioblastoma (Additional file 3:
Figure S2). We tested the levels of various transcription
factors, including Oct4 [21], Nanog [22], and Sox2 [23],
which are involved in the self-renewal of GSCs and the
expression of maternal embryonic leucine zipper kinase
(MELK) [24], and associated with GSC proliferation and
the expression of GSC markers such as musashi (Msi),
Nestin [25], and Aldh [3]. The results indicated that
disrupting the CXCR4 reduced the levels of Oct4,
Nanog, and the expression of Msi and MELK, and
slightly reduced the expression of β-intergrin, Nestin
and Aldh; the level of Sox2 and Lin 28 remained un-
changed (Figures 2E, F). This indicates that the CXCL12/
CXCR4 axis plays a significant role in maintaining the
self-renewal properties of GSCs.Disrupting SDF-1/CXCR4 differentially increases the
apoptosis of RG2 induced by cytotoxic chemotherapy
GSCs are characterized by drug resistance. To test how
disturbing CXCR4 affects the drug resistance and cytotoxic
chemotherapy of glioblastoma, we used temozolomide
(TMZ) [26] and 1, 3-bis (2-chloroethyl)-1-nitrosourea
(BCNU) [26,27], which are alkylating drugs frequently used
DNA to treat brain tumors. We first examined the optimal
dosage of TMZ and BCNU for killing RG2 cell lines. The
apoptotic effect of TMZ was not obvious until the concen-
tration reached 900 μM, whereas BCNU exhibited an apop-
totic effect at a concentration of 100 μM (Figures 3A, B).
In normal medium conditions, both the shGFP and
shrCXCR4 were treated using 900 μM of TMZ or 100 μM
of BCNU. The apoptotic index was defined as the fold of
the apoptotic population of treated cells compared
with the apoptotic population of vehicle-treated cells.
Disrupting the SDF-1/CXCR4 pathway only slightly in-
creased the cytotoxic effect of TMZ; however, reducing
CXCR4 expression significantly increased the cytotoxic ef-
fect of BCNU (Figure 3C). Several molecules have been im-
plicated in the drug resistance of CSCs. In particular,
MGMT has been suggested in both TMZ and BCNU re-
sistance. We performed semi-quantitative RT-PCR to ex-
plore the expression of molecules implicated in the drug
resistance of CSCs, including ABCb1A, ABCb1B [3], and
MGMT [28]. The results showed that the expression of
these molecules increased in cells isolated from the sphere
formed by shGFP RG2. In addition, the expression of
MGMT was higher in shGFP compared with shrCXCR4
RG2, whereas the level of ABCb1A and ABCb1B increased
slightly in shrCXCR4-1, compared with the levels of these
molecules in shGFP (Figure 3D).
Disrupting the expression of CXCR4 impairs
vascularization of xenografts derived from rat RG2
glioblastoma cells
Evidence indicates that the SDF-1/CXCR4 axis significantly
contributes to intratumoral angiogenesis [29]. To explore
the role of CXCR4 in regulating the vascularization of glio-
blastoma, either shrCXCR4-1, or shGFP were intracranially
injected into NOD-SCID mice. In accordance with the
subcutaneous xenografts, hematoxylin and eosin (H & E)
staining indicated that disrupting the CXCR4 did not im-
pair in vivo tumorgenesis, but the tumors derived from
CXCR4-deficient cells were smaller than those derived
from shGFP. The proliferating cells as indicated by PCNA
were reduced in the xenografts derived from the CXCR4-
deficient cell lines. However, more cells spread from the
center of the tumor derived from the control cell lines
(Figures 4A-D). After anti-CD31 staining, we observed that
more CD31 positive microvessels sprouted from the tumor
derived from control cells than those from CXCR4-
deficient cell lines (Figures 4E-H). A quantitative analysis
Figure 2 CXCR4 is required by glioblastoma cell lines for maintaining self-renewal characteristics of cancer stem-like cells. (A) Flow cytometry
using anti-CD133 and RT-PCR indicated that RG2 had a low level of CD133. (B) Spheroid formation of the control shGFP and shrCXCR4 RG2 after culture
in an ultralow dish for 10 d. Quantitative analysis showed a reduced number (C) and size (D) of spheres derived from the shrCXCR4 RG2 clone. Similar
results were obtained from 2 independent experiments, and each experiment was performed in triplicate. (E) Histograms of cell cycle analysis showed
that the deficiency of CXCR4 caused the reduction in G1 and the increase of G2/M populations. After being cultured in an ultralow dish 7d, the spheres
derived from shGFP and shrCXCR4-1 were collected and trypsinized, and cell suspensions were subjected to PI staining. Comparing the cell cycle profiles
revealed that the percentage of G2/M populations within cells collected from shrCXCR4-1 spheres (S-shrCXCR4, 19.5 ± 0.7%) was higher than those
derived from shGFP (S-shGFP, 15.5 ± 0.6%) (*P< 0.05). By contrast, the percentage of G1 population within cells collected from shrCXCR4-1
(68 ± 0.8%) was lower than those from shGFP (72 ± 1.5%, *P< 0.05). (F) Western blot analysis showed that disrupting CXCR4 reduced the level of
stem-cell-associated genes, including Oct4 and Nanog. (G) RT-PCR assay indicated that the expression of several genes, including stem-cell markers, Aldh,
Nestin, Msi, and the proliferation promoting gene MELK increased in the control clone after forming spheroids, but decreased in the shrCXCR4-1 RG2.
The shown were one of the similar results from 2 independent experiments.
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Figure 3 Disrupting the CXCL12/CXCR4 axis increased the sensitivity of glioblastomas to antineoplastic drugs. To investigate the effects
of disruption of the CXCL12/CXCR4 axis on drug resistance, cells were plated at a density of 10 000 per well in a 12-well plate 1 d prior to drug
treatment. TMZ or BCNU was added to achieve the indicated concentrations on the day of the experiment. After 24 h, cells were collected, fixed,
stained with propidium iodide (PI) according to standard protocols, and analyzed. The histograms of flow cytometry showed that the RG2 cells
were highly resistant to TMZ (A), but only slightly resistant to BCNU (B). Two independent experiments were done in triplicate and yielding
similar results. As shown is the representative from one experiment. (C) Under normal-medium conditions, both shGFP and shrCXCR4 were
treated with 900μM of TMZ or 100 μM of BCNU. PI staining revealed that the disruption of CXCR4 significantly increased the susceptibility of RG2
to BCNU, but only slightly increased its susceptibility to TMZ. The apoptotic index was defined as the fold of the apoptotic population of treated
cells compared with the apoptotic population of vehicle-treated cells. Two independent clones of siGFP and shrCXCR4 were used to perform the
experiments, yielding similar results. Each clone was used to perform 2 independent experiments in triplicate. (*t test, P < 0.05). (D) RT-PCR
indicated that disrupting CXCR4 disturbed the expression of genes associated with drug resistance in GSCs.
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significantly reduced the intratumoral microvessel density
(iMVD) (Figure 4M). The results also showed that CXCR4
deficiency led to a reduction in PAS-positive intratumoralvessel density (Figures 4K, L, and N). However, in the
shrCXCR4-1 xenografts, the density of the PAS-positive
vessel was 20% (PAS: CD31: 25 vs. 18) higher compared
with the CD31-positive vessel. This indicates that
Figure 4 Disruption of the CXCL12/CXCR4 axis impaired the neovascularization of rat RG2 glioblastoma in vivo. (A, B) H&E staining of
sections collected from orthografts showed more cells sprouting from the tumor core from the control shGFP RG2 (A) than from shrCXCR4 RG2
(B) (red arrow: sprouting RG2 cells). (C, D) Immunohistochemistry using anti-PCNA staining showed more proliferating cells spreading in the
sections collected from grafts of shGFP RG2(C) than those from shrCXCR4 (D). Immunohistochemistry using anti-CD31, an endothelium cell
marker, showed more CD31-positive microvessels in the grafts derived from shGFP RG2 (E, G) than in those derived from shrCXCR4 (F, H). The
CD31 positive tubes were sprouting from the tumor core in the sections from the grafts of shGFPRG2. (red arrows, CD31 positive vessels
surrounded by cancer cells). (I, J) The levels of VEGF were reduced in the grafts derived from shrCXCR4-1 RG2 (I), compared to those from shGFP
RG2 (J). (K, L) PAS, a marker of basement membrane staining, indicated that more PAS-positive microvessels existed in tumors derived from
shGFP (K) than in those derived from shrCXCR4-1 (L) (red arrow, PAS positive tubes). (M, N) Quantitative analysis showed that the density of
CD31 positive (M) and PAS-positive (N) microvessels was higher in the tumor derived from shGFP. (O) RT-PCR indicated that disruption of CXCR4
reduced the expression of genes regulating angiogenesis, including VEGF, ANGT1, MMP2, and MMP9, but not VE-cadherin. Arrowheads, the
boundary of the tumor core, *result from zymography. *t test, P < 0.05.
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CXCR4 disruption. To explore the molecules involved in
angiogenesis, we performed RT-PCR to detect the expres-
sion of VEGF, VE-cadherin [30,31], angiopoietin 1(AGNT1) [32], MMP2 [33], and MMP9 [34], and of
shrCXCR4 and shGFP RG2 cells. The result showed that
disrupting CXCR4 impaired the expression of VEGF,
AGNT1, MMP2, and MMP9, whereas it increased the
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molecule that controls cellular junctions and blood vessel
formation (Figure 4O). In addition, gelatin zymography
showed reduced activity in the matrix metalloproteinases
(MMPs), which are molecules involved in vascularization
(Figure 4O*). This suggests that the CXCL12/CXCR4 axis
is critical to the vascularization of glioblastoma.Discussion
In accordance with previous studies, we demonstrated that
the CXCL12/CXCR4 axis plays a substantial role in regu-
lating the proliferation, drug resistance, and neovas-
cularization of glioblastoma. However, the current study is
the first to show that CXCR4 plays a critical role in
maintaining the CSC characteristics of rat RG2 glioblast-
oma. The results show that disrupting CXCR4 selectively
reduces the level of Oct4, Nanog, and MELK, but not that
of Lin28 and Sox2. This suggests that the reduction of
Oct4, Nanog, and MELK resulted from the destruction of
CXCR4 signaling, rather than the change of cell fate. The
data suggest that CXCL12/CXCR4 executes this function
through the ERK and AKT pathways, regulating the ex-
pression of Oct4, Nanog, and MELK [35].
The current study was the first to show that RG2 has
a high capacity for forming spheroids, exhibiting high
levels of the molecules involved in maintaining the prop-
erties of stem-like cells. In addition, the expression of
the ALDH, ABCG2, CXCR4, Nestin, and Msi, CSC
markers was elevated in the cells of spheroids derived
from shGFP (Figure 4). This indicates that RG2 cells
have a cancer stem-like population. Although the results
show a level of CD133 in RG2, this challenges CD133 as
an obligate CSC marker [19]. The findings demonstrated
that RG2 is highly prolific, invasive, and drug resistant.
Thus, we speculate that RG2 has a stem-cell like popula-
tion, comprising a low CD133 levels that may represent
certain types of human glioblastoma.
Scholars have suggested that GBM GSCs that express
high levels of MGMT are the key components that cause
resistance to therapy. TMZ is the primary chemothera-
peutic molecule used to treat GBM. The DNA adducts
generated by TMZ are removed by MGMT [36,37]. In
the current study, we determined that RG2 cells, similar
to GSCs, express MGMT and are highly resistant to
TMZ. Disrupting CXCR4 resulted in the impaired resist-
ance of RG2 to both TMZ and BCNU, suggesting that
impaired resistance to these molecules is caused by the
reduced expression of MGMT. However, the knockdown
of CXCR4 has distinct effects on the expression of ABC-
transporters ABCb1B and ABCb1A. The results indicate
that CXCR4 plays distinct roles in modulating the ex-
pression of molecules implicated in the expulsion of
toxic agents.Scherer suggested that the perivascular space contained
specialized properties that are critical to maintaining
and spreading glioblastoma [38]. Studies have found that
these specialized properties include maintaining a stem-
cell-like phenotype in glioblastoma cells localized in the
niche region [39,40]. Therefore, the perivascular space is
thought to contribute to tumor growth and therapeutic re-
sistance. Rao et al. and other scholars determined that
targeting the CXCL12/CXCR4 pathway can abrogate a
specialized trophic function of GBM-associated vascula-
ture that contributes to brain tumor growth [41]. Further-
more, Farin et al. observed that GBM cells travel along
blood vessels and pause at select vascular branch points to
proliferate [42]. In agreement with their findings, our re-
sults from the intracranial xenograft model reveal that
disrupting the CXCL12/CXCR4 pathway reduces both the
vessels that sprout from the tumor core and the
intratumoral microvessel density. A decreased number of
satellites was also observed in the grafts from shrCXCR4-
1 RG2 (Additional file 4: Figure S3), indicating the de-
creased invasiveness of shrCXCR4 RG2. The current study
also showed that the CXCL12/CXCR4 axis may regulate
angiogenesis by regulating the expression of VEGF,
ANGT1, and MMP9, which are major contributors to
angiogenesis. However, the results of PAS staining and the
increased expression of VE-cadherin indicate that blocking
the CXCR4 pathway may not completely abrogate
vascularization [31]. This may explain why RG2 continued
to generate tumors despite the disrupted expression of
CXCR4. The in vitro invasiveness assay suggested that the
CXCL12/CXCR4 pathway is not vital to the migration of
RG2 glioblastoma. In vivo observations indicated that the
role of the CXCL-12/CXCR4 axis in the local recurrence
or invasiveness of glioblastoma may be vital in modulating
the ability of glioblastoma cells to proliferate and induce
angiogenesis, but not to migrate [38,43,44].
Conclusions
By using rat RG2 glioblastoma, we showed that
disrupting the CXCL12/CXCR4 axis impairs the charac-
teristics of GSCs. CXCR4 is known to be involved in the
proliferation and angiogenesis of glioblastoma and in de-
termining its invasiveness and resistance to drugs. In
contrast to previous findings, we characterized the
CXCL12/CXCR4 axis by using the RG2 cell line. The re-
sults suggest that CXCL12/CXCR4 is involved in the
progress of glioblastoma, regulating the expression of
the molecules associated with stem-cell properties. The
importance of characterizing RG2 lies in the continual
demand for experimental neuro-oncology animal models
that can be used to assess the efficacy of new approaches
for treating brain tumors. Although previous evidence
has suggested that CXCL12/CXCR4 is an effective thera-
peutic target for glioblastoma, our findings elucidate the
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gress of glioblastoma, additionally clarifying the proper-
ties of rat glioblastoma for use as an animal model in
the treatment of brain tumors.
Materials and methods
Cell culture and transfection
RG2 cells (provided by the laboratory of Dr. Ma) were cul-
tured in 90% Dulbecco’s modified Eagle’s medium that
contained 10% fetal bovine serum, which was supple-
mented using 4 mM of L-glutamine adjusted to contain
1.5 g/L of sodium bicarbonate and 4.5 g/L of glucose,
penicillin (100 U/mL), and streptomycin (100 mg/mL)
(Invitrogen Life Technologies, Carlsbad, CA, USA). The
cells were transfected as described in [45]. Cells at
approximately 80% confluence in 3.5 cm culture plates
(Falcon) were transfected with 8 μg of total DNA by using
lipofectamine (Invitrogen Life Technologies) according to
manufacturer protocols. Following transfection, the cells
were selected using 600 μg/mL of G418 and individual
colonies were picked up. The expanded colony was main-
tained in a selective medium that contained 300 μg/mL of
G418. The expression and level of CXCR4 were deter-
mined using RT-PCR and western blotting, respectively.
The CXCR4 deficient clones were designated shrCXCR4
and the control clones were designated shGFP.
Intratumoral microvessel density (iMVD)
Depending on the size of the H & E section, 5 to 8 areas
within the tumor were randomly selected for evaluation
at 100X magnification. These areas were subsequently
used to analyze the iMVD measurements at 200X mag-
nification. The MVD was measured according to the
Weidner method [46]. Each positive endothelial cell
cluster of immunoreactivity that contacted the selected
field was counted as a single vessel, including the mor-
phologically identifiable vessels with lumens.
Animals and generation of xenografts
We performed animal experiments in accordance with
the Experimental Animal Management Ordinance ap-
proved by the Institutional Animal Care and Use Com-
mittee of the National Defense Medical Center of Taiwan.
Each experimental group used 5–6 four- to eight-week-
old female NOD-SCID mice. Each mouse was injected
intracranially or subcutaneously with 2.5 × 106 CXCR4-
deficient cells (shrCXCR4 RG2) or the aforementioned
control, shGFP RG2 [47]. After 2 months, the animals
were anesthetized, and 4 μM paraffin-embedded sections
of the brain or xenograft tissues were prepared for immu-
nohistochemistry. The sections were stained using H & E
and examined using a microscope for the presence of
metastatic tumor foci (satellites).Western blotting
For the cell lysate preparation, the cells were washed using
prechilled in phosphate buffered saline and lysed in an HI-
RIPA buffer comprising 20 mM of Tris–HCl, pH 7.5;
150 mM of NaCL; 2 mM of EDTA; 1 mM of sodium fluor-
ide; 0.5% Triton X-100; 0.5% sodium deoxycholate; 0.5%
SDS; 10% glycerol; 1 mM of sodium orthovanadate; 1 mM
of PMSF; and 1 mg/mL of aprotinin and leupeptin (freshly
prepared). Protein assay, SDS PAGE, and western blotting
were performed to conform to standard procedures.
Additional file 5: Table S2 lists the antibodies and condi-
tions used in western blot and immunohistochemistry.Plasmid of shRNA and reverse transcriptase polymerase
chain reaction (RT-PCR)
Regarding the RNAi of CXCR4, we expressed the shRNA
molecules targeted at sites beginning at Nucleotide 22.
Additional file 6: Table S3 lists the oligonucleotides used
to target the shRNA to the CXCR4, and the control GFP
(synthesized by Integrated DNA Technologies, Coralville,
IA, USA). The oligonucleotides were annealed and ligated
into a pSilencer 2.1-U6 neo (Ambion, Austin, TX, USA),
according to manufacturer directions. The constructs
were sequentially verified.
Regarding PCR, 80% confluence of shGFP, shrCXCR4,
and sphere shGFP (S-shGFP) cells were collected and
immediately lysed using a Trizol reagent (Invitrogen
Tech), and the total RNA was isolated. For each popula-
tion, the first-strand DNA (cDNA) was formed using 5
μg of total RNA according to the Superscript III First
Strand Synthesis System (Invitrogen Tech.). Additional
file 6: Table S3 lists the sequences of primers used to
amplify the indicated genes with PCR (MDbio Inc,
Taipei, Taiwan). PCR was performed using 30 cycles of
denaturation at 94°C, annealing at 55°C–60°C for 1 min,
and elongating at 72°C for 1 min.Drug treatment and cell apoptosis assay
The cells were plated at a density of 105 per well in a
12-well plate 1 d prior to the drug treatment. TMZ
(Sigma) or BCNU (Bristol-Myers Squibb, Princeton, NJ,
USA) was added to achieve the indicated concentrations
on the day of the experiment. After 24 h, the cells were
collected, fixed, stained using propidium iodide (PI)
according to standard protocols, and analyzed using
a Partec Cyflow ML flowcytometer (Partech GmBH,
Münster, Germany). The relative percentage of cells in
each cell-cycle compartment was estimated using Cell
Quest Pro (BD Biosciences). The apoptotic index was
defined as: the % of apoptotic cells treated using drugs
at the indicated time intervals/the % of apoptotic cells
treated using a vehicle at the indicated time intervals.
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The cells were cultured on a 10 cm ultralow plate at a
density of 1000 per mL by using 10% FBS medium
[48,49]. After 7 d, the cultures were collected in a 15 mL
centrifuge tube and left standing for 3 min to precipitate
spheres. The supernatant was discarded and the spheres
were gently suspended using a 2 mL medium without
FBS, then separately plated into a 12-well plate. Images
were captured at 8X magnification. All the spheres were
counted and their sizes was determined as follows:
extralarge: diameter > 2 mm; large: diameter 1.5 mm–
2 mm; medium: diameter 1.0 mm–1.5 mm; small: diam-
eter < 1 mm.
Statistical analysis
All data for the colony formation, invasion, iMVD, and
proliferation assays were expressed using the stand error
mean. The means between the two groups were com-
pared using a two-tailed Student t test, and a P < 0.05
was considered statistically significant.
Additional files
Additional file 1: Figure S1. A high level of CXCR4 is associated with
malignant brain tumors, but not with normal brain tissues. To investigate
the correlation between CXCR4 levels and clinical pathological statuses, a
primary brain tumor high-density (208 cores) tissue array of astrocytoma,
glioblastoma, glioblastoma multiforme (GBM), and normal tissues was
used to perform immunohistochemistry. The array contained triplicate
cores per case: 60 cases of cancer and 9 cases of normal tissue. After
CXCR4 staining, the tissue with a weak or no signal of CXCR4 was
grouped in CXCR4 low (A, B) and the tissue with a high intensity of
CXCR4 was grouped in CXCR4 high (C). The results indicated that a high
level of CXCR4 was associated with malignant tumors (D). The
pathological status also correlated with the level of CXCR4 (Additional
file 2: Table S1). These findings suggest that CXCR4 plays a role in the
progress of primary tumors.
Additional file 2: Table S1. A high level of CXCR4 is associated with
the pathological status of glioblastoma.
Additional file 3: Figure S2. Disruption of CXCR4 results in RG2
proliferation deficiency and the increase of apoptosis in vivo. To explore
the effect of CXCR4 disruption in the tumorigenesis of GSC in vivo,
shrCXCR4-1 cells and shGFP cells were subcutaneously injected into
NOD-SCID mice. After 21 d, both shrCXCR4 and shGFP cells grew to
tumor mass. Xenografts derived from shrCXCR4 showed a tumor mass
size that was smaller than those derived from shGFP (A, B).
Immunohistochemistry using anti-PCNA, a proliferating cell marker, was
performed to explore the proliferating cells of sections obtained from
shGFP and shrCXCR4 xenografts. The PCNA-positive population of
xenografts derived from shGFP was 70% and significantly dropped to
50% of those derived from shrCXCR4 (C, D). PCNA index: PCNA positive
cells (brown)/hematoxylin positive cells (blue). The results showed that
there were fewer proliferating cells in the xenografts derived from
shrCXCR4-1 than those in the xenograft derived from shGFP. The
apoptotic cells were revealed by TdT labeling by using TACS2 TdT-blue
label in situ apoptosis detection kit (Travigen, Inc. Cat. 4811-30-K). The
result showed that the apoptotic population of xenografts derived from
shGFP was 30% and significantly increased to 40% of those derived from
shrCXCR4 (C TdT labeling, D TdT labeling index). TdT labeling index: TdT
label positive cells (blue)/nuclear fast red positive cells (red). This
observation suggested that CXCR4 plays an essential role in the
proliferation of glioblastoma cells. *t test, P < 0.05.Additional file 4: Figure S3. Disruption of CXCR4 markedly reduced
the number of satellites, which were defined as tumor foci with blood
vessel and away from the tumor core (TC). H&E staining revealed a
reduced number of satellites (arrow) in the intracranial grafts from
shrCXCR4-1 RG2 (B) as compared with those from shGFP RG2 (A).
(C) Average of number of satellites per xenografts, indicating less number
of satellites in the xenografts derived from shrCXCR4 RG2 as compared
with those derived from GFP RG2. Number of satellites was counted as
the average of 6 adjacent sections of each grafts. Representatives are the
average number of satellites from 5 xenografts derived from shrCXCR4
or shGFP RG2.
Additional file 5: Table S2. Listed antibodies for immunoblot blot
and immunohistochemistry.
Additional file 6: Table S3. Listed primers for RT-PCR.
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